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Abstract

This paper addresses the issue of counterfeit pharmaceuticals, using the
supply chain as a lens through which to view problems and resolutions. The issue of
counterfeit pharmaceuticals is one that is only going to increase in magnitude, and
the proliferation of internet access greatly impacted the counterfeiter’s role. As more

consumers have gained access, the internet has become a viable venue through

which to purchase and sell counterfeit products. Through the research of this topic,
the hope was to suggest possible resolutions for the supply chain and major

stakeholders. Because of the illegal nature of the issue of counterfeit

pharmaceuticals, accurate empirical data was largely unavailable. However, the
Food and Drug Administration and the World Health Organizations were the two most

informative sources. Concluding this research, I have found that the issue of
counterfeit pharmaceuticals is one that needs much more attention than is currently
being dedicated. Through government initiatives, such as the Prescription Drug

Marketing Act, and IMPACT, the entire supply chain should be more integrated in

their resolve to thwart the increase of counterfeit pharmaceuticals in the United
States.

ii

Table of Content

Introduction....... .............................................................................................. 4

1.

Research Methodology.....................................

8

III.

Wellness and Recovery: The Impact of Counterfeit Drugs....................9

IV.

Legal Perspective.........................................

V.

A Brief History of Counterfeit Drugs in the Global Marketplace......... 16

VI.

Internet and Technology...........................................................

VII.

Pharmaceutical Goods: A Case History of Abuse...................................... 22

VIII.

Why Prevalence of Counterfeit Drugs is growing so rapidly in USA... 26

IX.

Supply chain Issues and Counterfeit Drugs............................................... 29

X.

The Role of Supply Chain Members and Control of

^g

Counterfeit Drugs..................................................................

XI.

Conclusion............

XII.

Bibliography............................................................................

XIII.

Appendix............. ..... ....................................................................

40

45

49

52

Introduction

Counterfeit goods hold an established position in the history of this civilized

world. As early as the fourth century, counterfeiters have attempted to profit by
deceiving the public1. As a country matures economically, the amount of regulation
and emphasis put on providing safe healthcare increases. The United States has
developed into the established economy that it is today, and several administrations

exist to regulate the pharmaceutical industry. However, within the last decade, the
Food and Drug Administration’s counterfeit drug investigations have risen

significantly in the United States2. The World Health Organization reports that in

2010 the counterfeit pharmaceutical sales have risen 92% in the US since 1995.
This 92% increase in sales means there is now a $75 billion dollar industry for

counterfeit pharmaceuticals.3 These numbers paint an alarming picture of the
counterfeit pharmaceutical industry in North America. We, as Americans, have been

comparably protected and sheltered by the rules and regulations set forth by the

1 Lybecker, Kristina. “Keeping it Real: Anticounterfeiting Strategies in the

Pharmaceutical Industry.” Managerial and Decision Economics 29 (2008):
389-495 Web. Nov. 2011

2 United States. House. Committee on Government Reform. Sick Crime: Counterfeit

Drugs in the United States. 109th Congress. First session. Washington:
Government Printing Office, 2006. Print.

3 http://www.who.int/mediacentre/news/releases/2006/pr09/en/
4

Food and Drug Administration (FDA). Unfortunately, following the development of the
internet and less expensive technologies, the United States is struggling to thwart the
increase of counterfeiters.

Throughout the rest of the world, many countries are unable to effectively
regulate the production and distribution of counterfeit pharmaceutical goods, either

by a lack of laws and regulations or a lack of effective implementation of these laws
and regulations. Countries such as China and India have struggled with containing

the problem of counterfeit medicines throughout recorded history, and this struggle
is still evident today. The FDA claims that up to 15 percent of the drugs sold

throughout the world are counterfeit. This number rises to as much as 50 percent in

parts of Africa and Asia.4 Although the prevalence of counterfeit drugs increase in
developing countries, the issue of counterfeit pharmaceutical products plagues every

country in the world, and the final consumer ultimately pays the price, both with their

wallet and with their health.

The final consumer of a counterfeit drug may be very likely to suffer from
alarming consequences. Also, the lack of treatment that the consumer would have

received had they not consumed the counterfeit drug may also be a major detriment
to a person’s health. This paper will not only focus on the negative consequences of
final consumption, but will also address the issues that the wholesaler, retailer,

4 Mathuna, Donal P., McAuley, Adam. “Counterfeit Drugs: Towards an Irish Response

to a Global Crisis.” (2005): Web Nov. 2011 (in the section “assessing the
extent of the problem)

5

manufacturer, and consumer will encounter relative to obtaining pharmaceutical
drugs. Another facet to the issue of counterfeit pharmaceutical goods includes that

of detection. Unlike luxury goods, where you may be able to tell how a Louis Vuitton

purse is stitched, pills themselves do not contain indicators that are easily

recognizable. Therefore, without the use of rather advanced technology, the
detection of counterfeit drugs becomes near to impossible in most instances. The
standardized property of the pills themselves do not allow for consumers to deduce
the quality of the medicine without relying wholly on the brand name or the

pharmacists’ recommendation. The packaging is the main indicator of a quality drug,

and with developments in technology, counterfeiters are now able to reproduce
labels with alarming accuracy.

In this paper, I will analyze the various ways that counterfeit drugs are
introduced into the value chain from manufacturer to ultimate consumer, and the
different ways that counterfeit drugs may affect the final consumer. There are

varying degrees as to how much active ingredient a counterfeit drug may contain.5
The severities of the consequences of consuming counterfeit pharmaceuticals also

vary dramatically. If the drug is completely counterfeit, the consumer doesn’t receive

any of the medicinal value that is sought. If the drug contains only a portion of the
active ingredient, then the virus or bacteria that the consumer is intending combat

5 Forzley, Michele. “Combating Counterfeit Drugs: A Concept Paper For Effective
International Cooperation.” World Health Organization, Health Technology and

Pharmaceuticals: International Conference - Rome, Italy (2006): Web Jan.

2012

6

develops antibodies, and becomes resistant to what the normal drug would contain.
These two examples assume that the inactive ingredient of the counterfeit drug is not

harmful to one’s health. That being said, counterfeit pharmaceutical goods may not
only contain little to no active ingredient, but may also contain substances that could

possibly cause harm to the consumer’s health and possibly prove to be fatal.6

Without investing in an effective system of detection that is translated across
all four sections of the supply chain, counterfeit pharmaceutical increasingly

becomes a threat to the overall health of society.

6 Ibid
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Research Methodology
In researching this topic, I have utilized EBSCO host and Google scholar,

because these two sources have current articles pertaining to this topic as well as
research that has been done over the last two decades. This will be my main source

of information because the books that are available on this topic are somewhat out

of date and do not contain the most current information. World Health Organization
has a website that publishes a lot of information regarding what is currently being

done to combat counterfeit pharmaceutical drugs. In addition to the WHO website,
the FDA also has published information regarding this issue. Also, I have consulted

news articles to gather as much up-to-date data as possible. “Empirical, reliable, and
transparent statistics about drug counterfeiting are virtually non-existent.”7

7 Outterson, Kevin: Smith, Ryan. “Counterfeiting drugs: The Good, the Bad, and the
Ugly." Albany Law Journal of Science and Technology 16 (2006) Pg. 527 Web.
March 2012
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Wellness and Recovery: The Impact of Counterfeit Drugs

The relevance and importance of intellectual property rights becomes a more

critical issue as countries progress from emerging to developed economies. The
differences between developments of countries around the world could have a

negative impact on the effectiveness of laws pertaining to intellectual property rights.

This not only causes some areas of trade and international relations to be

complicated but also increases the opportunities to find loopholes and to twist the
system into something that can be potentially harmful to many people.8 When
companies choose to manufacture their goods in a foreign country, they run the risk

of exposing their product to counterfeiters. The differing intellectual property laws
make it profitable and sometimes even legal for these counterfeiters to produce

products without the consent or knowledge of the legitimate manufacturer.

The pharmaceutical industry of the United States is unique in that the rules

and regulations of the FDA apply to both manufacturing firms located in the US and
firms manufacturing outside of the US. Even though the intellectual property rights

laws may differ from country to country, the FDA regulations remain the same across
country borders for American businesses. Although this regulation should be

effective in securing the supply chain of the United States, evidence has shown us

8 Cabezas, Maria Dolores. “Counterfeit Medicines as Global Treat.” Pharmaceuticals
Policy and Law 12 (2010): 179-192. Web. Dec. 2011. Pg.181

9

that counterfeit drugs often slip through the cracks and unscrupulous behavior is still

quite prevalent. The drug manufacturers themselves only need to comply with the

FDA for safety, effectiveness and labeling of their drugs. After the drugs leave the
manufacturer, the FDA has little control over where they go; which frequently includes

the secondary market9. The limited jurisdiction of the FDA leaves the state to
implement standards for distributors10. These standards often leave room for
unscrupulous persons to take advantage of the opportunities that exist in buying and

selling pharmaceuticals.

The regulation that the FDA provides to manufacturers does not translate to

the commerce of internet pharmacies. Because the internet isn’t regulated, internet
pharmacies cannot guarantee as to where the drugs are coming from or what types
of regulations are required of manufacturers.

9 United States. House. Committee on Government Reform. Sick Crime: Counterfeit
Drugs in the United States. 109th Congress. First session. Washington:

Government Printing Office, 2006. Print. Pg 2

10 Ibid
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Legal Perspective

The many facets of intellectual property rights include trademarks, counterfeit
goods, and patents. Intellectual property rights provide a foundation for countries to
be able to effectively and productively participate in global trade of the 21st century.

The use of intellectual property rights also provides incentives for countries to be
innovative. Although effective use of intellectual property rights is essential to a

country’s economic development, many countries classified as developing, often lack
the resources necessary to enforce the laws and regulations surrounding intellectual

property rights. 11

According to the World Health Organization, "counterfeiting occurs both with

branded and generic products and counterfeit medicines may include products with
the correct ingredients but fake packaging, with the wrong ingredients, without active
ingredients or with insufficient active ingredients.”12 Pharmaceutical products and

medicines are a unique category of intellectual property rights that has escaped the

11 Forzley, Michele. “Combating Counterfeit Drugs: A Concept Paper For Effective

International Cooperation.” World Health Organization, Health Technology and
Pharmaceuticals: International Conference - Rome, Italy (2006): Web Jan.

2012 Pg. 3

12 World Health Organization. (2006) "Counterfeit Medicines”
http://www.who.int/medicines/services/counterfeit/impact/lmpactF S/en/
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attention of many because of the difficulty in monetizing their value and to be able to

maintain their value to the organization. The act of producing a counterfeit medicine,

like that of other counterfeit goods, disregards the rights that an original producer
owns. Because the counterfeiter has little regard for the legality of the good, they
could also very easily have little regard for making sure the medicines have the

correct amount of active ingredients, which would increase the probability of causing
harm to the final consumer. The unique nature of modern medicines includes the

fact that ultimate consumers are typically unlikely to be able to analyze the drug itself

and make judgments on its legitimacy. The properties of most medicines, and
increasing accessibility of drug making technology allows for counterfeiters to
produce a pill that is almost indistinguishable from an authentic drug.13 {The most
common property of a pill would be small enough to swallow, found, as to not hurt
when being swallowed, and color may vary.} Consequently, most consumers rely

completely on the pharmaceutical industry’s labelingof a drugto provide a legitimate

and safe product with the correct amount of active ingredient. This reliance on the
pharmaceutical industry causes many consumers to unknowingly risk their health

and even their lives when ingesting counterfeit drugs that were originally intended to
save their lives and improve their health.

When the drugs leave the manufacturer, they often pass to and from several

distributors. This provides opportunities for unscrupulous distributors to alter the
packaging, the labels, and add inactive ingredients to the medicines. The FDA has
attempted to curb these opportunities with the Prescription Drug Marketing Act

(PDMA). Enacted in 1987, the PDMA included:
13 Ibid: 21.

12

“a requirement for state licensure of wholesale distributors of prescription
drugs; a requirement that wholesale distributors of prescription drugs who are

not authorized distributors provide a statement of origin, also known as a drug
"pedigree,” to each wholesale customer. The pedigree traces each prior sale,

trade, or purchase of the prescription drug; and requirements regarding the

distribution and accountability of drug samples.”14

The technology that is required to trace and track the drugs requires financial
investments from the manufacturer, distributor, and retailer. Because of a lack of

support from the pharmaceutical industry, the PDMA received many complaints and
delayed requiring companies to implement the changes until 2006.15

In order to address the growing concern of counterfeit pharmaceutical

products (CPP) many organizations including the US Food and Drug Administration

(FDA), the World Health Organization (WHO), and the World Trade Organization (WTO)
are and have been gathering information from many countries around the world and
analyzing it in order to reduce the negative impact of counterfeit pharmaceutical
products as much as possible.16 In February of 2006, the WHO introduced a task

force specific to fighting counterfeit pharmaceuticals, called the International Medical

14 United States. House. Committee on Government Reform. Sick Crime:

Counterfeit Drugs in the United States. 109th Congress. First session.
Washington: Government Printing Office, 2006. Print. Pg. 25

15 Ibid: 26.
16 Forzley, Michele. “Combating Counterfeit Drugs: A Concept Paper For Effective

International Cooperation.” World Health Organization, Health Technology and
Pharmaceuticals: International Conference - Rome, Italy (2006): Web Jan.

2012

13

Products Anti-Counterfeiting Taskforce (IMPACT).17 IMPACT is made up of five
departments that focus on the following: “legislative and regulatory infrastructure,

regulatory implementation, enforcement, technology, and communication.”18 Those

five department are the, “communications, legislative and regulatory infrastructure,
regulatory implementation, enforcement, and technology working groups.”19 IMPACT

is focusing on providing a comprehensive framework of guidelines to the

pharmaceutical industry. The five departments are committed to raising awareness
of the issue of counterfeit drugs to all parties involved, improving upon the safety

requirements, such as providing sufficient labeling for products, attempting to secure

the distribution aspect of the supply chain, and investigating a region's capacity to

prosecute and combat counterfeiting.20

Because of the scope of combating counterfeit drugs includes laws and
regulations, it is clear that the supply chain alone cannot effectively prevent many
counterfeit goods from entering a country or supply chain; consequently a country’s

17 World Health Organization. (2009) "An Overview of the IMPACT Working Groups' documents
and activities"

http://www.who.int/impact/activities/overviewoflMPACTworkingdocs.pdf

18 World Health Organization. (2012) “IMPACT”

http://www.who.int/medicines/services/counterfeit/faqs/count q-a/en/
19 World Health Organization. (2009) "An Overview of the IMPACT Working Groups' documents

and activities"
http://www.who.int/impact/activities/overviewoflMPACTworkingdocs.pdf
20 Ibid
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government, the WHO, and other health oriented organizations have been and are

going to be critical in the prevention of counterfeit pharmaceutical drugs distribution.

As drugs move from manufacturers to the final consumer, there are many

opportunities for unscrupulous entities to infiltrate the system and exploit the
practices of a legitimate supply chain. Focusing on the dangerous effects of
counterfeit pharmaceuticals that are specific to each section of the supply chain, this

paper will analyze the four sections of the supply chain and will suggest strategies
that would reduce the likelihood of counterfeit pharmaceuticals entering the supply

chain. This will include the manufacturing, wholesaling, retail and consumers. A

transparent and thorough coordination between the four sections of the supply chain
is essential to reduce the volume and increase the prevention of counterfeit

pharmaceuticals entering a market; however, the ideal supply chain costs a business
time and money.

15

A Brief History of Counterfeit Drugs in the Global Marketplace

When examining the issues associated with counterfeit drugs from a global

perspective, the overall implications become much more serious. This is partly
because the regulations of the pharmaceutical industry and laws of different

countries allow for numerous opportunities to insert counterfeit pharmaceuticals into
the supply chain.21 The varying laws also come into play in internet pharmacies. In

addition to the discrepancies between laws, the varying economic situations in
relatively poor countries often force consumers to consider more economically viable
prices.22 Consequently, the final consumer has a much higher probability of

obtaining a counterfeit drug in less developed countries.

The phenomenon of counterfeit pharmaceutical drugs is much more prevalent

in underdeveloped and developing economies because of various economic and
cultural reasons.23 Counterfeit pharmaceuticals has affected both developed and

21 Forzley, Michele. “Combating Counterfeit Drugs: A Concept Paper For Effective
International Cooperation.” World Health Organization, Health Technology and

Pharmaceuticals: International Conference - Rome, Italy (2006): Web Jan.
2012 Pg. 4.

22 Cabezas, Maria Dolores. "Counterfeit Medicines as Global Treat.” Pharmaceuticals
Policy and Law 12 (2010): 179-192. Web. Dec. 2011. Pg. 180

23 Ibid
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developing countries; however, "weak drug regulatory control and enforcement,
scarcity and/or erratic supply of basic medicines, unregulated markets and
distribution chains, high drug prices, and significant drug differentials”24 dramatically

increase the prevalence of counterfeit pharmaceuticals in a particular country or

region. Although developed countries such as America seemingly have a smaller
percentage of counterfeit pharmaceuticals than do developing countries, due to the
internet and increasingly sophisticated technology, any type of economy in the world
is becoming more and more susceptible to counterfeit pharmaceutical drugs.25 This

is partly due to the fact that the punishment for such a crime is fairly light in some

areas of the world.26 In the past decade, the underdeveloped and developing
economies have taken measures to increase the severity of the punishment that
comes with being involved with counterfeit pharmaceutical goods. Adopting harsher
punishments may reduce the incentives that counterfeiters may have to get involved

24 http://www.who.int/mediacentre/factsheets/2003/fs275/en/
25 Lybecker, Kristina. “Rx Roulette: Combatting Counterfeit Pharmaceuticals in

Developing Nations.” Managerial and Decision Economics 28 (2007): 509
520 Web. Dec. 2011 Pg. 511

26Forzley, Michele. “Combating Counterfeit Drugs: A Concept Paper For Effective
International Cooperation.” World Health Organization, Health Technology and

Pharmaceuticals: International Conference - Rome, Italy (2006): Web Jan.
2012 Pg. 15
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in such a practice.27 “Perhaps the best way to describe the motivation behind

counterfeiting is offered by security chief Jackson of Novartis:
"Pretend that you graduated from the 'University of Crime' and you are
considering two career options. Which path you would follow? First, you can
manufacture and sell cocaine, and if you get caught, you may spend 20 years
or more in jail. Your second option is to manufacture and sell counterfeit

pharmaceuticals. If you get caught, in many jurisdictions, you'll be sentenced

to prison for two years and may be back on the street in six months."28
However, harsher punishment will not deter every counterfeiter as is seen in
the illegal drug trade. This is due to the fact that the benefits of a higher profit

margin outweigh the negative consequences of being punished in many economically
unstable countries.

The severity of the counterfeit pharmaceutical industry increases as one
considers the types of people and organizations who profit from this industry.
Organized crime is a major player in the world of the production of counterfeit

pharmaceutical goods.29 In order for this system of counterfeit pharmaceuticals to

take place, a country’s level of corruption should come into consideration.

27 Cabezas, Maria Dolores. “Counterfeit Medicines as Global Treat.” Pharmaceuticals

Policy and Law 12 (2010): 179-192. Web. Dec. 2011. Pg. 183

28 http://www.usatodav.eom/monev/industries/health/drugs/storv/2011-10-09/cnbc-drugs/50690880/l
29Lybecker, Kristina. “Rx Roulette: Combatting Counterfeit Pharmaceuticals in

Developing Nations." Managerial and Decision Economics 28 (2007): 509

520 Web. Dec. 2011 Pg. 512.
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Internet and Technology

A major contributing factor to the dramatic increase of counterfeit drugs in the
last decade or so has been the internet.30 Through connecting the world, the

internet has made it possible for almost anyone in any country to connect to another
person or place. Unfortunately, connections made through the internet also include

unscrupulous members of society, such as counterfeiters. The rapid development of
the internet has made it easier for counterfeiters to establish an online presence,
and has provided a vehicle for counterfeiters to connect with their clients and to

more easily disperse a growing amount of counterfeit drugs.31 Also, a lack of
regulation on the internet makes it extremely hard to restrict the sale of any type of
good, including counterfeit goods. Important technological advances of this decade

not only include the proliferation of access to the internet, which has greatly

increased the amount of counterfeit pharmaceutical goods available for sale, but
also includes ways to more effectively track and monitor the distribution of
pharmaceutical products.

30 Cabezas, Maria Dolores. "Counterfeit Medicines as Global Treat.” Pharmaceuticals
Policy and Law 12 (2010): 179-192. Web. Dec. 2011. Pg. 179.

31 Letkiewicz, Slawomir; Andrzej, Gorski. "The Potential Dual Use of Online

Pharmacies.” Science and Engineering Ethics 16 (2010): 59-75 Web. Nov.
2011 Pg. 63.
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Technology plays a major role in the production and distribution of
pharmaceutical goods. Within the United States of America, the Food and Drug
Administration is one of the major sources of innovation behind anti-counterfeiting

efforts.32 Whether through more effective research and development methods or
through the methods used to track goods in the supply chain, the pharmaceutical
industry is thriving with innovation. Unfortunately, as technological information has

become more easily accessible, many counterfeiters around the world have gained
access to these technological advances and have exploited them.

According to the Massachusetts Institute of Technology Auto-ID center, the
two major ways to monitor the supply chain system is through tracking and tracing.
Tracking is defined as, “knowing the physical location of a particular drug within the

supply chain.” Tracing is defined as, “the ability to know the historical locations, the
time spent at each location, the record of ownership, the packaging configurations

and environmental storage conditions for a particular drug.”33 Tracking and Tracing
forms the basis for, "improved patient safety by giving manufacturers, distributors

and pharmacies a systematic method to detect and control counterfeiting, drug

32 Koh, Robin; Schuster, Edmund; Chackrabarti, Indy; Bellman, Attilio. “Securingthe

Pharmaceutical Supply Chain.” Auto-ID Labs at MIT. White Paper. (2003) Web.

Nov. 2011

33 Koh, Robin; Schuster, Edmund; Chackrabarti, Indy; Bellman, Attilio. “Securing the

Pharmaceutical Supply Chain.” Auto-ID Labs at MIT. White Paper. (2003) Web.
Nov. 2011. Pg. 4.
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diversions, and mishandling”.34 A system of tracking and tracing requires equipment
and a technological infrastructure. The cost of manually inspecting the drug batches
becomes extremely expensive, thus the use of a comprehensive, automated system
of checking for drugs becomes necessary. The one thing that makes tracking and
tracing possible is the assumption that the entire supply would be working together.

Organizations independent of the pharmaceutical industry are recognizing the

urgency behind counterfeit pharmaceutical goods. Another innovation was recently

developed in the past two years. Sproxil, an independent company, has developed a

system that is used in conjunction with a Mobile Product Authentication Service. The
products that are registered with Sproxil all have a numeric code on the product itself.
The consumer can text the code to Sproxil and receive confirmation of whether or not

the drug is legitimate.35 36 This technology has been put into use in underdeveloped

countries and has reduced the risks of unknowingly purchasing a counterfeit drug.37
Through the development of technologies, the reduction of consumption of

counterfeit pharmaceutical goods will be possible.

__ _____________________________

34 Ibid

35 http://Sproxil.COmhttD://iiDsr.com/V2l7/6%20Vol.%202%20(7).%2QIJPSR289,%202011,%20Review%206.pdf
36 http://ijpsr.com/V2l7/6%20Vol.%202%20(7),%20IJPSR-289,%202011,%20Review%206.pdf
37 Ibid
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Pharmaceutical Goods: A Case History of Abuse

The issue of counterfeit pharmaceuticals necessitates urgent attention from
the public, government, and the pharmaceutical industries around the world. In
order to convey the urgency of addressing counterfeit pharmaceutical goods, I would

like to analyze a case in which the infiltration of counterfeit pharmaceutical goods
into the legitimate supply chain causes physical harm to the final consumer, and in
turn harms the companies that were involved in allowing the product to reach the
consumer. One recent instance of counterfeit medicine that has been discovered to
be counterfeited is the cancer medicine, Avastin. By looking at the case of Avastin,

we can see the side of counterfeiting that makes its way into the supply chain. The
case of Avastin illustrates key issues in the pharmaceutical industry and supply chain,
such as dealing with pharmaceuticals manufactured abroad.

Although the FDA and WHO have attempted to implemented regulations, and

have brought their attention to the counterfeit drugs market, this counterfeiting of
Avastin brings to light the complexities behind the pharmaceutical industry and the

ways reasons why it is extremely difficult to regulate and monitor this industry.

Avastin is the best selling cancer treatment drug in the United States that was

discovered to be counterfeit in February 2012.38 It is produced by a Swiss company,
Roche. They have a production branch located in San Francisco, California. This

http://www.npr.org/templates/storv/storv.php?storyld=147582172
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drug treats cancers of the colon, lungs kidneys, and brain. The counterfeit drugs that

were found contain no active ingredient, which is key to the treatment of cancer,

bevacizumab.39 The counterfeit version of the drug, Avastin, was also found to have
labels written in French.40 Another deviation included differences in the lot number

of the counterfeit drug and the lot number of the legitimate drug. Without knowledge
of what to look for in terms of packaging, the doctors and medical professionals were

not able to distinguish between a counterfeit version of Avastin and the real deal.

According to the WSJ, Avastin passed through wholesalers in Switzerland,

Denmark, and the UK, before coming to the US. The Middle East may be a possible
source of the counterfeit Avastin, however, it is unclear as to whether the Middle East

is the producer of counterfeit drugs, or whether they are acting as a transmit corridor,

or both.41

According to the Wall Street Journal, a 400-millligram vial of Avastin, costs

$2,400. This cost provides great incentives for counterfeiters to start producing this

drug. According to the FDA, the drugs were purchased by 19 medical practices in the
39 The New York Times. (2012) "Roche Says Counterfeit Avastin Distributed in the U.S.
Market” http://0www.lexisnexis.com.umiss.lib.olemiss.edu/hottopics/lnacademic/?shr=t&csi=6742&sr=

HLEAD(Roche+says+coiinterfeit+Avastin+distributed+in+the+U.S.+market)+and+date+is

+February,%202012
40 Ibid

41 The Wall Street Journal. (2012) "Tracing Fake Avastin to the Mideast” http://O-

search.proquest.com.umiss.lib.olemiss.edu/docview/923176870/fulltext7ac

countid=14588
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United States.42 Before arriving at the practices, packages of Avastin were purchased

from a foreign supplier, Quality Services Products.43 Volunteer Distributors, a
company in Tennessee, then distributed the drugs to the 19 medical practices.44 The
counterfeit version of Avastin did not contain any harmful substances, however it did

lack the helpful substances.

Refer to figure 1 in the appendix to see illustrations of differences and

similarities in the packaging.

Avastin is an example of how counterfeit drugs can leak into the legitimate
supply chain in the US. The FDA and the United States government passed the
Prescription Drug Marketing Act in 1988, which prohibits re-importation of drugs by

any drug entity other than the manufacturer.45 Although this act is intended to

eliminate the influx of foreign counterfeit drugs, the FDA has no authority to inspect
foreign drug distribution system; therefore, until the drug has made its way into the
households of Americans, the FDA has no power to actively pursue the elimination

and punishment of foreign counterfeiters.

Figure 2 in the index illustrates the intended results of the Prescription Drug

Marketing Act.

42 Ibid
43 Ibid

44 The Wall Street Journal (2012) “US Finds Fake Cancer Drug” http://Osearch.proquest.com.umiss.lib.olemiss.edu/docview/921412814/fulltext?accountid=145

88
45 US Food and Drug Administration (2003) “Background: Vulnerabilities in the US
Drug Distribution System” http://www.fda.gov/Drues/DrufiSafety/ucml74479.htm
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The case of Avastin illustrates the fact that the prevention of an influx of
counterfeit drugs not only requires government intervention, but it also requires

diligence and ethical behavior from the distributors.

Although the pharmaceutical industry has implemented regulations, the
internet is not regulated, and the pharmaceuticals bought from internet pharmacies
can very easily be a front for a counterfeiting organization. The internet is another
vehicle through which counterfeit drugs enter the United States. Online pharmacies

have attracted many consumers through low prices and privacy of at home delivery.
Whether they are aware or unaware, consumers are taking great risks when

purchasing drugs from online pharmacies. The anonymity of the internet has made it
into the most popular venue through which to buy counterfeit pharmaceuticals.
When purchasing drugs from an illicit online pharmacy, the entryway that is created

is often targeted by counterfeiters. The combination of small purchases from foreign

countries into large purchases makes it easier for counterfeiters to infiltrate America,
because the larger the volume of drugs, the more difficult it is for the FDA to intercept.
This is because there are many more resources focused on preventing small

quantities of drugs from entering the U.S. distribution system.46

46 Ibid
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Why Prevalence of Counterfeit Drugs Is Growing so Rapidly in USA

The World Health Organization estimates that 10%-20% of drugs in the entire
world are counterfeit.47 This number is assumed to be much lower in the United
States of America because of our highly regulated pharmaceutical industry. The

extent to which counterfeit medicines are a problem in developed countries such as
the US is minute compared to the some developing parts of the world. However, the
United States is not completely excluded from harm caused by counterfeit

pharmaceutical goods. In the US, The number of cases investigated has risen from

around five per year in the 1990’s to more than 200 per year in 2000 and to over
2000 per year in 2009.48 The increase is due to many different factors. K. N.
Lybecker points out that three of the factors that have increased counterfeiting
include, “increasing globalization, advancing technology, and the controversies

surrounding the WTO Trade-related Aspects of Intellectual Property Rights (TRIPS)
Agreement and access

47 Liang, Brian A. “Fade to Black: Importation and Counterfeit Drugs." American
Journal of Law & Medicine 32 (2006): 279-323. Web. Dec. 2011 Pg. 281

48 Cockburn R., Newton PN., Agyarko EK., Akunyili D., White NJ. “The Global Threat of
Counterfeit Drugs: Why industry and governments must communicate the
dangers.” PLoS MED 2(4): e1OO. (2005): 0302-0308. Web. Nov. 2011 Pg.

0302
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to medicine.”49 He suggests that the supply chain links also have room for

improvement. “Firms must ally themselves with their wholesalers, distributors,

retailers, and prescribers, securing each link in the supply chain. This will only be
accomplished through technology, cooperation across the supply chain, and by

enforcing efforts that safeguard product quality and intercept counterfeits.”50

The degree to which the public realizes the problem of counterfeit drugs is an

issue in both developed and developing companies. PLoS Medicine reports, “Many

pharmaceutical companies and governments are reluctant to publicize the problem

to the public of counterfeit drugs, seemingly motivated by the belief that the publicity
will harm the sales of brand-name products in a fiercely competitive business. In
order to avoid any alarm that could prevent patients taking their genuine medicines,
the pharmaceutical industries justify this secrecy.”51 Consumer awareness is an

increasingly important aspect of the problem of counterfeit pharmaceutical drugs
due to the increased control of consumers. Largely because of the internet,

consumers have gained access to more vehicles through which to buy drugs;
therefore, they are given more opportunities to search for the cheapest price.

49 Lybecker, Kristina. "Keeping it Real: Anticounterfeiting Strategies in the
Pharmaceutical Industry.” Managerial and Decision Economics 29 (2008):
389-495 Web. Nov. 2011 Pg. 390

50 Ibid

51 Cockburn R., Newton PN., Agyarko EK., Akunyili D., White NJ. "The Global Threat of

Counterfeit Drugs: Why industry and governments must communicate the
dangers.” PLoS MED 2(4): e100. (2005): 0302-0308. Web. Nov. 2011 Pg.
0302
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Because of the loose restrictions on the internet, it is difficult to verify the
authenticity of pharmaceuticals sold through this vehicle. So, although there is great

demand for discounted drugs on the internet, it is more dangerous to the consumer

to purchase reduced priced drugs on the internet. When examining counterfeit goods
in the pharmaceutical industry, the influence of the internet must not be excluded.

The high prices of many pharmaceuticals are a major motivating factor in the

purchase of counterfeit pharmaceutical drugs, not only in developing countries, but
also developed countries. Many factors determine the cost of a pharmaceutical drug.
In order to get a return on the cost of research and development, pharmaceutical

industries are able to patent their product for a length of 20 years. This system,
which was implemented in 1992, allows for a time period of heightened prices,

because the patents provide protection from competitors, the companies are without

incentives to lower prices. The high prices provide a higher profit margin for

counterfeiters and also a higher incentive for consumers to consider purchasing
drugs from a questionable source because of lower prices.

The weak punishment of counterfeiters is another reason why the practices of
producing and selling counterfeit drugs is so attractive. The FDA reports that the

amount of punishment for counterfeiting the label far outweighs the punishment

received for counterfeiting the drug itself.52

52 US Food and Drug Administration (2003) “Background: Vulnerabilities in the US
Drug Distribution System" http://www.fda.gov/Drugs/DrugSafety/ucml74479.htm
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Supply Chain Issues and Counterfeit Drugs

Another major problem in the pharmaceutical industry is its supply chain. The

3rd figure in the appendix illustrates three different distribution routes. The dotted

lines of the third route indicate potential illegal sales.53 The pharmaceutical supply
chain is complex to the point of being convoluted. The opportunities for

unscrupulous parties to enter this system are many because of its complicated
nature. Although counterfeiters sometimes reach consumers through the internet or

other sources, the supply chain still provides a viable and profitable market to be
targeted. This section will separate the supply chain into four parts: consumers,
retailers, wholesalers, and manufacturers. By separating these sections, I will
attempt to suggest improvements for each pharmaceutical at each separate level of
the supply chain.

Manufacturers

The manufacturers of pharmaceuticals are the producers of the drugs. This
requires a manufacturing plant where chemicals are combined and made into
medicines. In a legitimate plant, there are many safety regulations and many rules
provided by the FDA that make the transition of the medicines from the production

plant to the next section in the supply chain, usually the wholesaler, as smooth as
possible. Because of the nature of the product, it is imperative that these rules and

53 Ibid
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regulations be followed thoroughly. In a place where counterfeit medicines are

produced, there is little regulation, little regard for the well being of the final
consumer.

In most instances, the responsibility for providing a legitimate drug to the final
consumer is placed on the producer of the drug. If the drug is a generic, then the
accountability of the manufacturer is lessened greatly; however, in the case that the
drug carries the brand name of the manufacturing company, the public will place

most of the responsibility in the hands of the manufacturer. In The United states,
many pharmaceutical companies are reluctant to publicize the problem of counterfeit
drugs, mostly because they are motivated by the fear that the publicity will harm the

sales of their brand name product in a competitive business.54 An instance of
counterfeit drugs does have the potential to reduce the value of their brand name;
however, there are many cases in which drug companies have been very open with

the public about their struggles with counterfeit drugs. Johnson and Johnson set this

standard in 1982, when Tylenol was laced with cyanide.55 There is also an issue of
manufacturing companies being reactive instead of proactive in the battle of
counterfeit medicines. Because of the aggressiveness of the counterfeiters in recent

years, pharmaceutical companies are going to have to be much more proactive in

54 Cockburn R., Newton PN., Agyarko EK., Akunyili D., White NJ. “The Global Threat of
Counterfeit Drugs: Why industry and governments must communicate the
dangers." PLoS MED 2(4): elOO. (2005): 0302-0308. Web. Nov. 2011 Pg. 1

55 O’Rourke, Morgan. “Tylenol’s Headache” Risk Management 57.5 (2010): 8-9.

Web. Feb. 2012
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their regulations and rules. This will require the battle against counterfeit to become
much more of a priority in the pharmaceutical industry.

Another aspect of the pharmaceutical industry is the sometimes outrageous

pricing of certain drugs. There are many factors that contribute to the pricing of
counterfeit medicines. The major components of pricing are research and

development costs and promotional costs. Research and development is interesting

in the fact that it is extremely time consuming and expensive to produce a drug;
however, when competitors know the formula, it is costs much less to reproduce the

drug. To counter this, the pharmacy industry uses patents and a patent is another
factor that increases prices for consumers. In the US in particular, the only direct
interaction that manufacturers have with consumers is through direct-to-consumer

advertising. Therefore, the physicians and pharmacists are the only other
representations of drug companies that consumers come into contact with.

Pharmaceutical manufacturers are estimated to spend approximately $165 million in
promotional activities directed towards physicians who prescribe the drugs.56 The

costs of research and development can’t be easily eliminated; however, the cost of

promotions can be reduced and reducing the cost of promotion could reduce the
final cost to consumers.

56 Cravens, Karen S.: Glover, Hubert D. "Pricing complexities in the Pharmaceutical

industry: Implications for external auditors” Managerial Auditing Journal 10,7
(1995): Pg. 11. Web. Feb. 2012
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Manufacturing companies should be the catalyst for allowing the rest of the

supply chain to be held accountable. When choosing a wholesaler to sell to, they
should be fervently attempting to ensure prospective wholesalers are operating with
high business practice standards. Reducing the cost of promotions can greatly

reduce the cost to the final consumer, and can reduce the incentiveto counterfeit,

because the profit margin will be smaller.

Wholesalers
The wholesaling section of the supply chain has been credited as being the

weakest link. The United States has 3 major wholesalers: AmerisourceBergen Corp,
Cardinal Health Inc., and McKesson Corporation. These major wholesalers handle
from 80 to 90 percent of pharmaceutical products in the USA.57 The three major

wholesalers "stock thousands of drugs from hundreds of manufacturers". “They

procure almost all of their stock directly from producers and sell to most pharmacies
around the country.”58 The remaining 10-20 percent of pharmaceutical products
moves through a smaller secondary wholesaling system.59 This secondary system is
mainly used to compensate for shortages. Another interesting aspect to the

57 Lybecker, Kristina. “Keeping it Real: Anticounterfeiting Strategies in the
Pharmaceutical Industry.” Managerial and Decision Economics 29 (2008):
389-495 Web. Nov. 2011 Pg. 391

58 deKieffer, Donald. “Trojan Drugs: Counterfeit and Mislabeled Pharmaceuticals in

the Legitimate Market." American Journal of Law and Medicine 32 (2006):
325-349 Web. Nov. 2011 Pg. 328

59 Ibid: 391-392
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secondary wholesaling system is the fact that the three major wholesalers also

purchase from the secondary wholesalers. They primarily do this in order to find a

cheaper price. According to Donald deKieffer, the major distributors operate with a
very thin profit margin. Traditionally, purchasing cheaper drugs from a secondary
wholesaler has been too tempting for most of the major wholesalers to completely
resist.

Through this trading between wholesalers, counterfeiters are more easily able
to take advantage of the system. The transfer of drugs from wholesaler to wholesaler

requires that inventory be taken more often, and will have more opportunities to
overlook a possible counterfeit situation. Accordingto Abbot Laboratories,‘It is often
through a secondary market that counterfeit, adulterated or improperly stored and

handled products make their way into the distribution system. The secondary market

products are generally products purchased from any source other than from the
original manufacturer and are commonly referred to as secondary, gray or diverted

products. When the product comes from the secondary market it is difficult to assure
patients and healthcare professionals of the product’s quality or safety.’60 By selling

the drugs at irresistibly low prices, the counterfeiters are initially able to enter the
supply chain.

The wholesaling section of the supply chain is seemingly the weakest link in

the counterfeit pharmaceutical industry. This is partly because of the nature of the
wholesaling industry in general. These companies obtain profits by moving the
products from the manufacturer’s hands to the pharmacies. This may include

60 Ibid: 392
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several changes of possession before it reaches the final pharmacy. The more a
product changes hands, the more likely counterfeit drugs will be able to slip into the
supply chain.

Effective and enforced laws and regulations of a third party entity should have

the most impact on eliminating the opportunities for unscrupulous parties to sell
their counterfeit drugs into a legitimate supply chain. Also a reduction in the number
of times that pharmaceuticals change possession will reduce the opportunities to
purchase illegitimate pharmaceuticals. Additionally, a more regulated secondary
market will greatly reduce the opportunities for counterfeiters to enter the supply

chain.

Retailers

In the pharmaceutical supply chain, the retailer is the window through which

consumers are able to access drugs and to receive information about drugs. The
majority of medicines that are carried by retailers are purchased from three
wholesalers in USA. They are AmerisourceBergen Corp, Cardinal Health Inc., and

McKesson Corporation. Although around 80 percent of pharmaceuticals that
retailers carry are purchased from these three wholesalers, a secondary wholesale
market accounts for nearly 20 percent of purchases from the pharmaceutical

industry.61 The retailers in the United States are gradually becoming aware of the

scope of the problem of counterfeit medicines. Before 2005, CVS announced that it
will ‘no longer purchase drugs from wholesalers that trade in the secondary market,
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which has been a point of entry for counterfeit drugs into the supply chain.’62 As

mentioned before in the manufacturing section, a reactive attitude towards

counterfeit drugs will not be acceptable in the future. Pharmacies and hospitalswill
need to be proactive in reducing the amount of counterfeit drugs that come into
contact with the final consumer.

In order to intercept the entry of counterfeit drugs into the supply chain, the

pharmacies should be aware of the amount of responsibility they possess. Through
recklessly purchasing drugs from secondary markets, pharmacists are increasing

their risk of unknowingly purchasing a counterfeit drug. In addition to the strategies
that are already in place, pharmacies and hospitals should be more accountable for

the wholesalers that they are purchasing from. The pharmacists have extremely

important roles, including educating patients, making prudent purchases, and
detecting counterfeit drugs. These responsibilities are seemingly not a problem;

however, when detection of counterfeit pharmaceuticals includes the alteration of

business practices and added expense, the pharmacist may be inclined to turn a
blind eye.63

62 Lybecker, Kristina. “Keeping it Real: Anticounterfeiting Strategies in the
Pharmaceutical Industry." Managerial and Decision Economics 29 (2008):
389-495 Web. Nov. 2011 Pg. 399

63 Ziance, Ronald J. “Roles for Pharmacy in Combatting Counterfeit Drugs.” Journal of

the American Pharmacists Association 48.4 (2008): e71-e91. Web. Nov.
2011 Pg. 72
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In order to prevent counterfeit drugs from reaching the final consumers.
pharmacists should limit or eliminate or reduce the amount of purchases from
secondary wholesalers, and scrutinize their business practices. The pharmacies
should also be able to communicate effectively with consumers in a way that will not

cause any alarm. An inspection of the labeling and the pills themselves would also

help to prevent any counterfeit drugs from reaching the final consumer. These
actions that may be taken by pharmacies will make a substantial difference In the
amount of drugs that come into contact with the final consumer.

Drug Consumers

The nature of the pharmaceutical industry requires large sums of money

invested in the research and development of drugs. The investment that goes into
the development of drugs is usually reflected in the final prices of drugs. After the

research and development of the drug is complete, the actual manufacturing cost is
not high, but in order to recover costs of research and development, the final price of
the drug is usually set to be able to recover the high cost of the development until the

patent expires. This high price, not only entices counterfeiters to become interested
in the pharmaceutical industry, but it also causes many consumers to seek the

cheapest price regardless of the risks they may encounter. Where there is a demand
for something, there will usually always be a supply. One major eliminator of

counterfeit drugs would be a reduced profit margin for counterfeiters.

The internet has provided our society with countless advantages and
resources; however, when abused, it can be deadly. Many consumers are looking to

the internet for online pharmacies, where the prices are much cheaper than in brick
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and mortar pharmacies. The development of the internet and computers has
provided an easily accessible venue for which consumers are able to search for and

purchase the cheapest drugs.

The consumer has become an increasingly important link in the supply chain

because of the role that they are now playing in purchasing pharmaceutical products.
Through technological developments such as the internet, this increase in available

venues has increased the amount of responsibility that should be placed on the final

consumer. By purchasing a drug from an internet pharmacy, they are assuming that
the pharmacy is handling the drug as a brick and mortar pharmacy would. However,

according to an investigation conducted by the United States General Accounting
Office, online pharmacies were found to be generally unreliable. They obtained 68
samples of 11 different drugs and encountered many problems with the drugs, the

labeling on the bottles, and the online pharmacies themselves.64 Regardless of the

risk involved, many consumers are turning towards the internet to find cheap
pharmaceuticals. Internet pharmacies are fairly successful in world trade, and this is

reflected in their “high share in the general share of medications”. This amounts to

about a 10% share in the market of pharmaceuticals.65 This indicates the general

demand for online pharmacies. Although a large percentage of online pharmacies

64 Crosse, Marcia. “Internet Pharmacies: Some Pose Safety Risks for Consumers and
Are unreliable in Their Business Practices." Highlights of GA0-05-888T, a
testimony before the Permanent Subcommittee on Investigations, Committee
on Governmental Affairs, U.S. Senate. (2004) Web. Nov. 2011 Pg. 1
65 Letkiewicz, Slawomir; Andrzej, Gorski. “The Potential Dual Use of Online
Pharmacies.” Science and Engineering Ethics 16 (2010): 59-75 Web. Nov.

2011 Pg. 63
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are unscrupulous in their activities, many online pharmacies are legitimate

alternatives to the brick and mortar pharmacies.66 Because of the nature of the
internet, and the risk involved when purchasing anything on the internet, the

consumer should realize the amount of responsibility that is required when
purchasing pharmaceuticals from the internet. According to an Ernst and Young
study, "the internet and mail-order operations will be the biggest source of

counterfeit drugs over the next five years.’’67

The consumers who buy counterfeit pharmaceutical goods should be held

accountable as to what outlets they purchase medicines from. When buying
medicines from the internet, they should be aware of the associated risks.
Consumers should be more involved in the authenticity verification process. In many

developing countries, the involvement of the final consumer is crucial to the
consumers’ health. A company has produced Sproxil, which is a system that includes

a barcode that will allow the consumers to text the number on the medicines to a
company who texts back an OK if the medicines are legitimate. If they are not

guaranteed by the company, they will receive a NO. This involvement of the final
consumer has greatly reduced the amount of deaths due to counterfeits in
developing countries.68

66 Ibid
67 Lybecker, Kristina. "Keeping it Real: Anticounterfeiting Strategies in the

Pharmaceutical Industry.” Managerial and Decision Economics 29 (2008):
389-495 Web. Nov. 2011 Pg. 399

68 http://sproxil.com/
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in the supply chain, and as the
Consumers play an increasingly large role in

of society they will increasingly be
internet continues to pervade more aspects of society.
subject to risks - much of the time at their own doing.
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The Role of Supply Chain Members and Control of Counterfeit Drugs
In order to effectively participate in the efforts to reduce the amount of
counterfeit pharmaceutical goods, all the membersofa pharmaceutical good supply
chain must coordinate their efforts, A thorough coordination of efforts must entail:

1) More efforts focused on selection of quality drugs, not cheap drugs (a

movement away from secondary supply chain purchases).
2)

3)

Cooperation with the government in the area of prosecuting counterfeiters.

A movement towards a comprehensive supply chain tracking and tracing
system and the use of authentication technologies.

A pharmaceutical company, such as Roche, should have very specific ways in
which it should deal with counterfeit pharmaceuticals. Because of their recent

encounters with counterfeit Avastin, they should be looking to increase security of
their supply chain and deliver quality pharmaceuticals to their consumers. Among

other things, this would entail requiring pedigrees, requiring authentication
technologies, and limiting or carefully monitoring the importation of pharmaceuticals.

A pedigree states the source or origin of the medicine. It contains information about
all of the transactions that the drug undergoes. By requiring a pedigree, the drug

P nies will be able to ensure the quality of the drugs. An authentication process

way that pharmaceutical companies can combat counterfeit drugs from
entering their supply chain

This would require equipment and tools to evaluate
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whether the product’s labeling and packaging is the manufacturer’s original. The
authentication process has three different levels of involvement.69 The first one is

overt authentication. These are things that are visible to the eye, such as hologram
or distinct colors. Another, somewhat more expensive, mode of the authentication

process includes covert authentication technologies. This requires special
equipment and sometimes includes watermarks. These two methodswill require

some degree of investment in training and/or equipment. In order for these methods
to be effective in combating counterfeit goods, all members ofthe supply chain

should adopt these two authentication processes. Forensic technology is the final
and most sophisticated authentication technology. This type of authenticity requires

equipment usually found in a forensic chemistry lab. The more thorough a company
is with its authenticating products, the more confidence it can have about providing
quality drugs to its consumers. The third way in which US pharmaceutical companies
can guard themselves against counterfeits is through carefully considering which
wholesalers to use. The reputation of the wholesaler should be a major factor in

deciding whether or not to forge a business relationship. Although all of these

methods have the potential to greatly reduce the amount of counterfeit
pharmaceuticals being distributed to the final consumer, until the manufacturer,

wholesaler, and retailer are diligent in their efforts to deal with this problem, the

problem of counterfeit goods will always plague our society.

69 US Food and Drug Administration (2003) "Background: Vulnerabilities in the US

Drug Distribution System" http://www.fda.gov/Drugs/DruRSafetv/ucml74479.htm
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These steps towards securing a supply chain are extremely costly. The

authentication technologies require new equipment and maintenance of the
equipment. This also requires doctors and medical professionals to be trained in the

uses of these technologies. Although it is the hope that customer safety is first and
foremost in the minds of healthcare professionals, the costs of implementing these
technologies is often more than members of the pharmaceutical industry can bear.
Although the increased costs is often a great deterrent to investing in these

technologies, the longterm benefits may compensate for the short term costs.

According to the FDA, some of the longterm benefits would include, "improved
inventory management, reduced labor costs, reduction in theft, protection from

intentional tampering, and reduction in diverted products.”70

Ideally, through these steps, the supply chain will be able to sustain the

quality of medicines. Internet pharmacies, however, will only be changed through

raising customer awareness and cooperation from the government. These changes
will make it easier to maintain a channel of distribution that can be held accountable

by other members of the supply chain as well as by the general public.71 Because
the nature of the pharmaceutical industry is extremely complicated, secure business
practices are essential in diligently providing quality drugs to final consumers. The

two pronged entryway for counterfeit drugs entering the US include those that enter
through the supply chain and those that are bought from the internet. In order to

70 Ibid
71 Cabezas, Maria Dolores. “Counterfeit Medicines as Global Treat.” Pharmaceuticals

Policy and Law 12 (2010): 179-192. Web. Dec. 2011. Pg. 188
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lower the amount of drugs that are bought from the internet, consumers should be

aware of the risks that they are taking by purchasing drugs from an internet
pharmacy.

The priorities of a pharmaceutical good supply chain must be different from

the supply chains of many other goods. This is because the health of the consumer

relies completely on where they are positioned in the supply chain’s list of priorities.
Because the pharmaceutical industry has such a slim profit margin, the temptation to
search out the lowest prices and attempt to overlook the source the medicine may be

much greater in the pharmaceutical supply chain.

Creating, manufacturing, and selling a pharmaceutical product require many

to consider the costs of production and that of prevention. Prevention costs are that
which cover the cost of defective products. The more a company has to inspect its

goods for defects, the more it costs to operate a business. This aspect is an
incredible disincentive for businesses to actively participate in the reduction of

counterfeit pharmaceuticals beyond the point where their costs would be any higher.
“Raising the standards of intellectual property protection presents long-term benefits

but short-term costs.”72 Persuading members of the supply chain that the quality
and legitimacy of drugs are more important than the profit margins is going to be the
biggest obstacle of decreasing the amount of counterfeit pharmaceuticals that enter
the system.

72 Long, Clarisa. Intellectual Property Rights in Emerging Markets. Washington D.C.:
The AEI Press. 2000.

43

In order to effectively combat the rise of counterfeit pharmaceutical products,
a comprehensive and effective plan must be made that includes all members of the

supply chain. The plan must include incentivesand motivations for members of the
supply chain to invest more time and resources towards combating counterfeit
pharmaceutical. Impact is an international forum that exists to allow representatives
to convene and discuss measures that can be taken to combat counterfeit

pharmaceuticals. Although it has no actual power over the pharmaceuticla industry,
the rules presented in this document could presenta an effective way to combat

counterfeit drugs.

Another unique aspect of the pharmaceutical industry is the high cost of

research and development. Being able to take advantage of a lack of research and
development costs is a huge motivation for coutnerfeiters to begin the act of

producing or distributing counterfeit pharmaceuticals. This is because “in the
pharmaceutical industry, the discovery process is extraordinarily resource-intensive,

but once an effective drug is on the market, the compound is comparatively easy to
syntehsize.”73 Counterfeiters can relatively easily replicate the drug, and therefore

completely leave out the actual drug’s research and development costs. The
research and development costs are usually covered by a the final price of a drug.

Without having to cover costs for research and development, counterfeiters have a

great probability to make a large profit, with little production costs.

Ibid: 4
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Conclusion

The resolution to the problem of counterfeit pharmaceuticals is one that
encompasses the entire supply chain, the government, and education of the public;
and the battle with counterfeit drugs will continue to be a major problem in the world
for many more years. However, through the connection and cooperation of all of the

members of the supply chain, more effective actions can betaken to prevent
counterfeit drugs from entering the supply chain. This will start with the
manufacturer. Through implementation of tracing and tracking technologies, the

supply chain will be more easily able to be aware of what drugs are where. This is

assuming that the entire supply chain has necessary resources and capabilities to
implement this type of technology. The drug manufacturing companies should be the

catalyst to a comprehensive technological infrastructure that supports tracking and
tracing technologies. Additionally, the manufacturers need to be proactive in

choosing the wholesalers with which they engage in business transactions. The
manufacturer’s role in the supply chain and the final consumer’s experiences with

the drug is usually associated with the manufacturer’s brand name.

Counterfeit drugs enter the wholesaler section of the supply chain easier than

any other section. This is because of the complicated nature of the pharmaceutical
supply chain. The continuous purchase and selling of pharmaceuticals require
extremely efficient organization, and thus require a way to thoroughly track what
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medicines are bought and what medicines are sold. The secondary wholesalers add
to the confusion of the supply chain. Through the elimination orthorough monitoring
of secondary wholesalers, the pharmaceutical industry will be able to eliminate a

major area of weakness that counterfeiters often have opportunities to exploit. The
wholesaling business operates on the premise of buying drugs for discounts and
selling them for a profit. The goal of obtaining a profit often surmounts ethical

decision making by the wholesaling companies. In order to combat unethical
behavior in the wholesaling section of the supply chain, the FDA should raise the

standards that exist to obtain a license to operate as a wholesaler in the
pharmaceutical industry.

By educating patients, making prudent purchases, and detecting counterfeit

drugs, pharmacies can play a major role in preventing counterfeits from reaching the
final consumers. Also, the interactions that pharmacists have with pharmaceutical
consumers put the pharmacists in a position of being able to inform consumers of

issues that may exist in the pharmaceutical industry. Additionally, pharmacists hold

the power to discontinue purchasing from a wholesaler that has a debauched
reputation. The pharmacists themselves also have an obligation to become
educated on the drugs they purchase. This will include being alert and informed as

to news in the pharmaceutical industry.

Last, but certainly not least, the final consumers also have a major role to be

playing in this system. As the purchasing power of consumers grow, the need to
make informed purchases increases. The internet has introduced a seemingly
unlimited amount of venues through which to purchase pharmaceuticals. This has
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attracted many unscrupulous parties, and a large portion ofthe consumers in the
United States have yet to realize the serious implications that come from making

uninformed purchases of pharmaceuticals. In order to make better purchase
decisions, consumers should be able to access any information that involves
counterfeit goods. Available information is imperative in the consumer portion ofthe

supply chain.

Laws and regulations would have a major impact on the wholesaler section of

the supply chain. Through laws and regulations that restricted the use of secondary

wholesalers and required wholesalers to provide information about source of the

.
drug, the supply chain would be able to more effectively intercept counterfeits.

However, stricter laws and regulations would require more resources focused on the
problem of counterfeiting. This requires that resources be pulled from another area

of our society. The final consumer may also benefit from specific laws and

regulations regarding the purchase of pharmaceuticals on the internet; however, this
would require regulation of the internet. In addition to government regulations,
pharmaceutical companies themselves also have an obligation to require

wholesalers and distributors’ business practices to operate at a certain standard.
Turning a blind eye to the risk of purchasing a counterfeit because a business does

not want to pay an extra buck will not suffice in the near future. Counterfeiters have
already harmed many people in the pursuit of a profit, and in order to reduce the

amount of harm caused, the public, government, and organizations affiliated with

pharmaceutical companies will need to demand ethical business practices.
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In order to counteract the increased flow of counterfeits into the US, the
pharmaceutical industry should set high standards in the area of diligent business

practices. This will include tracking and tracing equipment, educated pharmacists
who will know how to look for a counterfeit, cooperation from the government in

i

harsher punishment of counterfeiters, and diligence in purchasing quality, legitimate

drugs.

This research highlights issues in the supply chain and what steps should be

taken as the pharmaceutical industry as a whole and what steps should betaken as
individual entities of the pharmaceutical industry. This research also brings to light

the overwhelming complexity of the pharmaceutical industry and ways in which the
government can assist in helping pharmaceutical companies deal with counterfeiters.
Also, the naiveness of the general public illustrates how vulnerable we are to
counterfeiters.

The problems of counterfeit pharmaceuticals plague developed and
developing countries, alike. Through effective cooperation of the entire supply chain,
participation of the government, and acknowledgment that the problem of counterfeit

drugs exist in America, we can begin to work together towards a realistic resolution
for the problem of counterfeit drugs.
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Figure 1:

Authentic Avastin FDA-Approved for Use in the United States

Counterfeit Product
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Figure 2:

Pre- and Post-PDMA
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Figure 3:

Drug Distribution Models
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